A study has identified a new biomarker, miR-519a-3p, for the early detection of Alzheimer’s disease in asymptomatic stages. This microRNA is linked to the cellular prion protein and is deregulated in patients with neurodegenerative diseases like Alzheimer’s. The research, led by the Institute for Bioengineering of Catalonia and University of Barcelona, aims to improve early diagnosis and treatment of Alzheimer’s. The study also confirms the specificity of this biomarker for Alzheimer’s, compared to other neurodegenerative diseases. The next step is to validate miR-519a-3p as a biomarker in blood samples for clinical diagnosis. This discovery offers hope for detecting Alzheimer’s disease before the onset of symptoms.
Source link
New biomarker identified to diagnose Alzheimer’s in asymptomatic stages
